Introduction
Patients’ Preferences for Osteoporosis Medications
First author | Country | Publication year | Method | Sample size | Funding | Number of attributes (or medications) | Main findings |
---|---|---|---|---|---|---|---|
Importance of medication attributes | |||||||
Weiss [12] | USA | 2006 | Survey (ranking and rating) | 3368 | Merck & Co. | 8 | Order of importance: effectiveness, side effects, interactions, out-of-pockets costs, time on market, dosing frequency, formulation, dosing frequency |
Duarte [13] | France, Germany, Mexico, Spain and UK | 2007 | Survey (ranking and rating) | 3000 | NR | 7 | Order of importance: effectiveness, side effects, out-of-pocket costs, dosing frequency, formulation, time on market, dosing procedure |
Hiligsmann [14•] | Belgium and Netherlands | 2013 | Nominal group technique | 26 | Amgen | 12 | Order of importance: effectiveness, side effects, frequency of administration and mode of administration, out-of-pocket cost, sequential therapy, place of administration, time on market, branded/generic, mono or combination, mode of action, cost for society |
Silverman [15•] | USA | 2013 | MaxDiff ranking | 367 | Novartis Pharmaceuticals | 4 | Order of importance: efficacy, safety, cost and convenience |
Conjoint analyses | |||||||
Fraenkel [18] | USA | 2006 | ACA | 212 | NR | 4 | Patients’ treatment preferences were strongly influenced by route of administration. Patients’ preferred treatment option, across all simulations, was bisphosphonates |
de Bekker-Grob [17] | Netherlands | 2008 | DCE | 120 | Public | 5 | All attributes (effectiveness, side effects (nausea), total treatment duration, route of drug administration, and out-of-pocket costs) were important Patients preferred a tablet once a month than tablet once a week or injection once a month or every 4 months |
Darba [16] | Spain | 2011 | DCE | 166 | NR | 3 | All attributes (route of administration, place of administration and costs) were important Patients preferred subcutaneous injection one per day rather than intravenous injection once per year |
Hiligsmann [19••] | Belgium | 2014 | DCE | 257 | Amgen | 5 | All attributes (effectiveness, side effects, mode and frequency of administration and costs) were important Patients preferred either an oral monthly tablet or 6-month subcutaneous injection above weekly oral tablets, 3-month subcutaneous, 3-month intravenous or yearly intravenous injections Patients disliked being at risk of gastrointestinal disorders more than being at risk of skin reactions and flu-like symptoms |
Structured interviews | |||||||
Gold [23] | USA | 2006 | 617 women currently using bisphosphonates | Interviews | Alliance for Better Bone Health | Two medications: weekly vs. monthly bisphosphonate therapy | More patients preferred weekly therapy over monthly therapy (82 vs. 18 %), after receiving information about fracture efficacy differences |
Keen [22] | UK, Germany, France, Spain and Italy | 2006 | 1253 currently taking a weekly bisphosphonate or had no current or prior history of bisphosphonate therapy | Interviews | NR | Two medications: weekly vs. monthly bisphosphonate therapy | 82 % preferred weekly bisphosphonate and 18 % monthly therapy Efficacy was the most commonly cited reason for this preference Overall, 69 % of patients intended to ‘definitely/probably’ use the weekly therapy compared with 34 % of women who rated the monthly therapy similarly |
First author and publication year | Country | Study duration | Sample size | Funding | Interventions | Outcomes |
---|---|---|---|---|---|---|
Crossover designs | ||||||
Freemantle [25], 2012 | USA and Canada | 2 years | 250 (221 in the second year) | Amgen | Denosumab vs. alendronate | Non-adherence less for denosumab (first year 11.9 vs. 23.4 %; second year 7.5 vs. 36.5 %) BMQ scores higher for denosumab Preference denosumab over oral therapy in 92.4 % |
Chung [29], 2009 | South Korea | 6 months | 365 | GSK Korea | Monthly oral ibandronate vs. weekly risedronate | Preference for once-monthly ibandronate in 74.8 % of patients Once-monthly ibandronate more convenient (84.2 %) than weekly regimen (15.8 %) |
Emkey [27], 2005 | USA | 6 months | 342 | Hoffmann-LaRoche, Ltd. GlaxoSmithKline | Weekly alendronate vs. monthly oral ibandronate | Preference for once-monthly ibandronate in 71.4 % Once-monthly ibandronate more convenient (74.6 %) |
Hadji [30], 2008 | USA, France and Germany | 6 months | 350 (321 in mITT) | Hoffmann-LaRoche Ltd. GlaxoSmithKline | Weekly alendronate vs. monthly oral ibandronate | Preference for once-monthly ibandronate in 70.6 % Once-monthly ibandronate more convenient (76.6 %) |
Kendler [34], 2004 | 19 countries in Europe, Middle East, the Americas and Asia-Pacific | 8 weeks | 406 | Merck | Daily vs. weekly alendronate | Preference for once-weekly dosing regimen in 84 % Once-weekly regimen more convenient (87 %) 84 % would be more willing to take it for a long period of time Adherence, 97 % for weekly tablets and 86 % for daily tablets |
Simon [31], 2002 | USA | 8 weeks | 288 | Merck & Co., Inc. | Daily vs. weekly alendronate | Preference for once-weekly regimen in 86.4 %, once-daily regimen in 9.2 %, no preference in 4.4 % Once-weekly regimen more convenient in 89.0 %, once-daily regimen in 7.7 % Long-term compliance believed to be better for once-weekly regimen in 87.5 % and once-daily regimen in 8.5 % |
den Uyl [24], 2010 | The Netherlands | 28 days | 102 | Nycomed Group AS/Roskilde, Denmark | Chewable tablet vs. sachet calcium and vitamin D | The mean number of days on drug was 12.8 days for the chewable tablet and 13.5 days for the sachet Preference for chewable tablet 67 %, for sachet 19 %, no preference (15 %) Acceptability variables (removing the dose from container, taking the dose, taste, time spent taking the dose and general convenience of taking the dose) were higher for the chewable tablet |
Open-label study | ||||||
Kendler [28], 2011 | USA and Canada | 1 year (first year of the study of Freemantle) | 250 | Amgen | Denosumab vs. alendronate | Preference lower for alendronate, both at baseline and after 6 months Satisfaction higher for denosumab and treatment bother higher for alendronate Non-adherence: 23.4 % for alendronate and 12.7 % for denosumab Risk ratios for denosumab compared with alendronate at 12 months 0.58 for non-adherence, 0.48 for noncompliance, 0.54 for non-persistence |
Bonnick [26], 2009 | USA | 6 months | 1678 | Roche and GlaxoSmithKline | Switch from weekly oral alendronate or risedronate to monthly oral ibandronate | Satisfaction scores improved 9 points by month 6 despite the high mean baseline summary scores (80.1 points) Convenience, overall satisfaction and quality of life domain scores improved. Increased satisfaction reported by 70.4 % of patients at month 6 Preference of once-monthly ibandronate 73.6 % (87.0 % of 1460 who completed Pref-Q) after 6 months |
Kastelan [35], 2008 | Croatia | 6 months | 258 | Not reported | Switch from weekly oral alendronate or risedronate to monthly oral ibandronate | Satisfaction higher with the monthly than weekly dosing Preference for once-monthly dosing in 94.7 %, once weekly regimen in 2.0 % and no preference in 3.3 % Quality of life improved in 85.9 % of patients, did not change in 9.3 %, worsened in 1.2 % with once-monthly ibandronate Once-monthly regimen more convenient in 93.0 % and once-weekly in 4.1 % |
Vlak [32], 2011 | Croatia | 6 months | 385 | Not reported | Switch from weekly oral alendronate or risedronate to monthly oral ibandronate | Increase in values of 4 domains of OPSAT-Q and CSS after switch |
Palacios [33], 2015 | Europe, USA, Australia and Canada | 1 year | 1703 | Amgen | Denosumab vs. monthly oral ibandronate (TTI) or vs. weekly oral risedronate (TTR) Patients previously treated with daily or weekly oral (TTR) or any (TTI) bisphosphonates with suboptimal adherence | Compared with baseline, patients in both treatment groups reported greater satisfaction in all TSQM domains at 6 and 12 months and changes from baseline persisted from month 6 to month 12 Changes in TSQM scores for all four domains were significantly greater in patients who transitioned to denosumab at all post-baseline time points, especially in the domains of convenience and global satisfaction |
McClung [36], 2007 | USA | 1 year | 225 | Novartis Pharma AG, Basel | Weekly oral alendronate vs. zoledronic acid intravenous infusion once-yearly | Preference for once-a-year infusion by 78.7 %; for once-a week oral regimen by 9 %; no preference in 11.8 % |